Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 14/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 4/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15017378 | 1.00 | NTRK1 (0.42) | NTRK1SMN1; SMN2KDM4ETSHRJAK2 | |
| SCHEMBL21097331 | 0.90 | NTRK1 (0.37) | NTRK1JAK2 | |
| SCHEMBL21097335 | 0.90 | NTRK1 (0.37) | NTRK1JAK2 | |
| SCHEMBL21097323 | 0.89 | NTRK1 (0.51) | NTRK1JAK2 | |
| SCHEMBL21097320 | 0.89 | NTRK1 (0.51) | NTRK1JAK2 | |
| SCHEMBL21097300 | 0.88 | NTRK1 (0.45) | NTRK1JAK2 | |
| SCHEMBL18049519 | 0.88 | NTRK1 (0.45) | NTRK1JAK2 | |
| SCHEMBL15017388 | 0.77 | NTRK1 (0.46) | NTRK1JAK2 | |
| SCHEMBL15017554 | 0.77 | NTRK1 (0.38) | NTRK1JAK2 | |
| SCHEMBL28673945 | 0.76 | NTRK1 (0.46) | NTRK1JAK2CCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10344031-B2 | Substituted pyrazolo[1,5-a] pyridine as tropomyosin receptor kinase (Trk) inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2019-07-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10344031-B2 | Substituted pyrazolo[1,5-a] pyridine as tropomyosin receptor kinase (Trk) inhibitors | MUSK, DMPK, PNCK | NTRK1 4/4885SMN1; SMN2 2317/4885KDM4E 2770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.